Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**RTIL-13** is a potent small molecule inhibitor of dynamin GTPase activity, exhibiting an IC50 of 2.3 μM against dynamin I GTPase. It was identified during the development of room-temperature ionic liquids (RTILs) for solubilizing the dynamin pleckstrin homology (PH) domain in dynamic combinatorial chemistry applications. The compound also interacts with pleckstrin homology lipid domains and shares structural features, such as an alkylammonium group, with other dynamin inhibitors like MiTMAB, suggesting a comparable mode of action, though not yet confirmed. Dynamin inhibition disrupts endocytosis, positioning RTIL-13 as a potential research tool for studying GTPase-related cellular processes.[1][4][16]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on RTIL-13.